Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,831 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06716606RecruitingPhase 3
Long-term safety of belimumab for lung disease in scleroderma and other connective tissue diseases
This study tests the long-term safety and effectiveness of belimumab for people with lung scarring caused by scleroderma or other connective tissue diseases. It is for patients who already completed a one-year study with belimumab and were not considered treatment failures.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06717412Recruiting
Low-dose conbercept for retinopathy of prematurity
This trial tests whether a low dose of conbercept, given as an eye injection, can safely treat type 1 ROP (an eye disease in premature babies). The goal is to stop abnormal blood vessel growth and prevent vision loss.
Xi'an, ShaanxiAges Any age - NCT06720987RecruitingPhase 1
KQB365 for advanced solid tumors with KRAS mutations
This trial tests a new drug called KQB365, alone or with other drugs, for people with advanced solid tumors that have a specific KRAS mutation (G12C or G12S). It aims to see if the treatment is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT06727721RecruitingPhase 2
Stem cell therapy for hard-to-treat type 2 diabetes
This trial tests a new stem cell treatment for people with type 2 diabetes that is difficult to control with standard medications. The treatment uses a special kind of stem cell to try to improve blood sugar levels.
ShanghaiAges 18–70 - NCT06728852RecruitingPhase 2
Vorolanib for advanced lung cancer after other treatments
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06728865RecruitingPhase 2
Furmonertinib plus Avastin for EGFR+ lung cancer with brain mets
This trial tests a combination of two targeted drugs (Furmonertinib and Avastin) as the very first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell) that has spread to the brain. The goal is to see how well it works and how safe it is.
Guangzhou, GuangdongAges 15–75 - NCT06731218RecruitingPhase 1
A study on RGB-5088 for type 1 diabetes
This trial tests a new treatment called RGB-5088 in people with type 1 diabetes. It aims to see if the treatment is safe and if it helps control blood sugar.
Tianjin, Tianjin MunicipalityAges 18–60 - NCT06731868RecruitingPhase 1/Phase 2
Study of an experimental tablet for tardive dyskinesia
This study tests an experimental once-daily tablet for moderate-to-severe tardive dyskinesia, a condition causing uncontrollable repetitive movements. It aims to see if the drug is safe and reduces these symptoms over time.
ShanghaiAges 18–64 - NCT06732505RecruitingPhase 1
Ac-225 DOTATATE for SSTR+ GEP-NETs: A Safety Study
This trial tests a new drug, Ac-225 DOTATATE, in people with a type of gut or pancreas tumor (GEP-NET) that has specific proteins (SSTR) on its surface. The goal is to see if it is safe and helps shrink or slow the tumor.
Beijing, Beijing MunicipalityAges 18–80 - NCT06732895RecruitingPhase 2
Weekly injection for teens with achondroplasia
This trial tests a weekly injection called navepegritide for adolescents aged 12-18 with achondroplasia (a common form of dwarfism). The goal is to see if it can safely improve growth. You must have a genetic confirmation of achondroplasia and a historical height measurement from the past 6 to 15 months.
MontrealAges 12–17 - NCT06733246Recruiting
Ceretrieve Device for acute ischemic stroke treatment
This study tests a new device called Ceretrieve that is designed to remove blood clots from large arteries in the brain for people having a severe ischemic stroke. If you are eligible, you will receive the device treatment (a mechanical thrombectomy) within 24 hours of your first symptoms.
HeidelbergAges 18 years+ - NCT06734221Recruiting
Testing a paclitaxel-coated balloon for leg artery disease
This trial tests a special balloon coated with a drug (paclitaxel) to open blocked leg arteries, aiming to improve blood flow and reduce symptoms like leg pain when walking. It is for people with moderate to severe leg artery disease who have not had prior stents or bypass in the treated area.
Chrzanów, MalopolskaAges 18 years+ - NCT06734637Recruiting
Peginterferon for essential thrombocythemia and polycythemia vera
This trial tests a medicine called peginterferon for people with two blood disorders: essential thrombocythemia (too many platelets) and polycythemia vera (too many red blood cells). The goal is to see if peginterferon can help control these conditions and is safe.
Wuhan, HubeiAges 18 years+ - NCT06736288RecruitingPhase 4
Buccalin® tablets to prevent repeat lung infections
This trial tests whether Buccalin® tablets can help adults who get frequent lower respiratory infections (like bronchitis or COPD flare-ups). It's a phase 4 study collecting more data on safety and how well the medicine works to prevent these infections from coming back.
AlessandriaAges 18–99 - NCT06741722RecruitingPhase 2
Study of mitoxantrone liposome combo for relapsed or refractory AML
This trial tests a new combination of drugs (mitoxantrone liposome plus others) for people with AML that has returned or hasn't responded to treatment. The goal is to see if the combination is safe and effective.
BeijingAges 18–75 - NCT06748352Recruiting
Robot-assisted scope removal for early stomach cancer
This study tests a new robot-assisted tool to remove early-stage stomach cancer or precancerous cells through a scope (endoscope) without open surgery. The goal is to see if it is safe and effective at removing the abnormal tissue completely.
Jinan, ShandongAges 18–80 - NCT06750289RecruitingPhase 3
Testing benralizumab for uncontrolled eosinophilic asthma
This study tests if adding a new injectable medicine (benralizumab) to your current medium-dose inhaler works better than simply increasing your inhaler dose to control hard-to-treat asthma. It may help people with a specific type of asthma linked to high eosinophil levels.
Chandler, ArizonaAges 12–75 - NCT06753981Recruiting
Triple drug therapy for new PAH patients
This trial tests whether a combination of three medications works well and is safe for people newly diagnosed with pulmonary arterial hypertension (PAH) that is not low-risk. It aims to see if starting with triple therapy early can improve outcomes.
Jinan, ShandongAges 18–80 - NCT06757153RecruitingEarly Phase 1
NRG-103 injection for recurrent glioblastoma patients
This trial tests an injection called NRG-103 given directly into the cavity where a recurrent brain tumor was removed. It is for people with glioblastoma that has come back and who have already had standard treatments.
Wuhan, HubeiAges 18 years+ - NCT06757244RecruitingPhase 2
Dovipa: Immunotherapy and vitamin D with chemo for advanced pancreatic cancer
This trial tests whether combining the immunotherapy dostarlimab with vitamin D3 and standard chemotherapy (mFOLFIRINOX) can help people with stage IV pancreatic cancer. It aims to see if this new approach is safe and effective.
MarseilleAges 18–75 - NCT06757504RecruitingPhase 2
Testing TTYP01 tablets for autism in kids and teens
This study tests an investigational tablet (TTYP01) to see if it can help adolescents and children with autism spectrum disorder (ASD). The goal is to find out if the drug improves symptoms and is safe for this age group.
BeijingAges 6–16 - NCT06758557RecruitingPhase 1/Phase 2
HB0025 for advanced solid tumors
This trial tests a new drug called HB0025 for people with advanced non-small cell lung cancer or endometrial cancer that cannot be removed by surgery. The study aims to see if the drug is safe and effective.
Baoding, HebeiAges 18–75 - NCT06758544RecruitingPhase 1/Phase 2
VRT106 plus chemo for resectable pancreatic cancer
This trial tests a new drug called VRT106 combined with chemotherapy for people with pancreatic cancer that can be surgically removed. The goal is to see if the combination works better than standard treatment alone.
Guangzhou, GuangdongAges 18–75 - NCT06758713RecruitingPhase 1
Gene-therapy treatment for blood cancers: safety and early effects
This trial tests a new kind of gene therapy (fourth-generation CAR-T) for several types of blood cancers including lymphoma, leukemia, and myeloma. It aims to see if the treatment is safe and starts to work against the cancer.
Guangzhou, GuangdongAges 18–75
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,831 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.